New: NCI-funded clinical trial search
Mednet Logo

What chemotherapy regimen do you recommend with radiation therapy for cervical esophageal squamous cell carcinoma?

The upfront plan is to use a definitive radiation dose of 66 Gy. My reading supports the use of 5FU + cisplatin but another doctor is recommending FOLFOX. The PRODIGE5/ACCORD17 trial, which examined the use FOLFOX, comprised mostly (all?) thoracic esophagus cancer, and RT doses were 50 Gy.
2 Answers
Mednet Member
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on

I would use weekly carboplatin/paclitaxel in this setting. Fluoropyrimidine + platinum is reasonable but will likely be more toxic, and I'm not aware of any data indicating that it's a more effective regimen.

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Medical Oncology · Dana-Farber Cancer Institute
Answered on

I have typically offered concurrent FOLFOX rather than 5FU/Cisplatin for definitive therapy of proximal esophageal cancers- either adenocarcinoma or squamous cell carcinoma. The former regimen is more likely to cause neuropathy but in my experience has been more tolerable than 5FU/Cisplatin. While not statistically significant, there were 6 toxic deaths in the 5FU/Cisplatin group versus 1 toxic death in FOLFOX group in PRODIGE5/ACCORD17 (p=0.066). Given the better convenience, perceived improvement in tolerability, and similar outcomes, I feel this is an appropriate 1st-line regimen to consider for definitive chemoradiotherapy.

I would have not employed Carboplatin/Paclitaxel when treating with definitive intent for a proximal lesion. While ...

Join for free or sign in to see the full answer